glp-1/gip agonist GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Curious about the latest in
Description
Tailoring treatment helps people lose fat while protecting muscle and function
DZIC is also the recipient of a 5 year CIHRKidney Foundation of Canada Team Grant Award
10.1111/bph.15059 73 ZhangL.LiC.ZhangZ.ZhangZ.JinQ
GLP-1 receptor agonist as treatment for cancer as well as diabetes: Beyond blood glucose control
Amylase Test Lipase Test Vitamin Tests: These are essential for detecting nutrient deficiencies, as GLP-1 medications may suppress appetite and reduce overall nutrient intake 13
PD clinical trials The neuroprotective effects of GLP-1RAs, particularly exenatide, seem to be more promising in PD
